Wegovy or Zepbound Out of Stock: What to Do Next

You have a valid prescription. You walked into the pharmacy, or got the dreaded callback, and Wegovy or Zepbound isn't there. Here's the part most articles still get wrong: in 2026, this is not a shortage problem. The FDA declared the semaglutide shortage resolved on February 21, 2025 (FDA: GLP-1 compounder policies) and the tirzepatide shortage resolved on October 2, 2024, then re-confirmed it in a December 19, 2024 declaratory order (FDA Declaratory Order on Tirzepatide). What you are running into is a distribution problem: independent pharmacies get smaller allocations, chains shuffle inventory by week, and higher doses get rationed.

There is a real playbook. If you want a provider that handles prescription transfers and insurance re-routing for you, Ro is the strongest fit for that specific job. The rest of this guide walks through what to do yourself, in order.

The 2026 reality: shortages over, stockouts not

The federal drug shortage list is the legal trigger that allows compounding pharmacies to make copies of FDA-approved drugs. Both semaglutide and tirzepatide came off that list in 2024–2025. That changed the regulatory landscape, but it did not magically equalize pharmacy inventory across the country.

In practice, three things still drive pharmacy-level stockouts in 2026:

• Allocation by distributor. Wholesalers ration high-demand medications by historical purchase volume. A small independent pharmacy with fewer prior fills gets a smaller share than a CVS or Walgreens.
• Dose-level rationing. Lower titration doses (2.5 mg Zepbound, 0.25 mg and 0.5 mg Wegovy) are easier to find than higher maintenance doses. The 12.5 mg and 15 mg Zepbound strengths and higher-dose Wegovy pens are where most people get stuck.
• Week-to-week inventory churn. A pharmacy that has your dose today may not have it tomorrow, and vice versa. Refreshing your search matters.

Translation: stop thinking "the drug is unavailable." Start thinking "this pharmacy doesn't have my dose this week."

Step 1: Don't panic, and don't silently skip doses

Before you start dialing pharmacies, contact your prescriber. The right move depends on where you are in your titration schedule and how long you've gone without a dose. Skipping or extending the interval between doses can affect tolerability if you have to restart a higher step. This is not something to figure out yourself.

Ask your prescriber two things: (1) is there a window I can safely wait without restarting at a lower dose, and (2) are you willing to authorize a transfer or write a new prescription if I find another pharmacy? Get the answers in writing or in the patient portal so you can move quickly when you find inventory.

Step 2: Use the manufacturer locator tools

Eli Lilly publishes a Zepbound Stock Locator at zepbound.lilly.com that shows pharmacy-level availability by ZIP code. It refreshes regularly and is the single best starting point for tirzepatide. It is accurate enough to rule out clearly empty stores, but call any pharmacy on the list before you drive — inventory can move faster than the tool updates.

Novo Nordisk does not currently publish a Wegovy-specific stock locator with pharmacy-level inventory data. For Wegovy, your two best signals are (1) the NovoCare Pharmacy direct-ship channel, covered in Step 6, and (2) calling around in your area, covered in Step 3.

Lilly also publishes a broader supply page at supply.lilly.com that confirms current production and shipping status for Zepbound across all dose strengths. It will not tell you which pharmacy near you has stock, but it will confirm that the medication is actively shipping, which rules out a manufacturing-side issue.

Step 3: Cast a wider net than the big chains

Most patients call CVS, Walgreens, and their mail-order plan, then give up. The bigger payoff is in pharmacies you don't normally use.

• Independent and compounding pharmacies (the legal, dispensing kind). They often use different wholesalers than the chains. Even small price differences in their allocations can mean inventory when the big stores are empty.
• Hospital outpatient pharmacies. Many hospitals have a retail pharmacy open to the public. They run on hospital-grade distributors and frequently have stock that the chains don't.
• Grocery store and warehouse pharmacies. Costco, Kroger, Publix, and HEB pharmacies are often overlooked. They have their own buying patterns.
• Sister branches of your usual chain. A CVS three miles away can have inventory the one across the street doesn't. Most chains let one location check inventory at others — ask them to do it.

When you call, ask three specific questions: "Do you have [exact dose] in stock right now?", "When is your next shipment expected?", and "Can I be added to a waitlist if you run out before I can get there?" Off-peak hours, mid-morning and mid-afternoon on weekdays, are when pharmacists have time to actually answer those questions.

Step 4: Request a pharmacy transfer the right way

Once you find a pharmacy with stock, you need the prescription moved over. Two paths:

• Patient-initiated transfer. Call the receiving pharmacy. Give them your current pharmacy's name and your prescription details. They will contact the sending pharmacy to pull the script. This is the fastest path when you've already located inventory.
• Prescriber-initiated transfer. Your prescriber writes a new prescription directly to the new pharmacy. Useful if the sending pharmacy is unresponsive or if your insurance routes through a specific pharmacy network.

The insurance side is where people lose time. If you have coverage and a prior authorization on file, ask your insurer whether the PA travels with you to the new pharmacy. For many plans, the PA is tied to the medication and patient, not the pharmacy — so a transfer within your plan's network does not require a new PA. For others, transferring outside your designated specialty or mail-order pharmacy does. Under federal CMS-0057-F rules in effect since January 1, 2026, impacted payers must return prior authorization decisions within 72 hours for expedited requests and 7 calendar days for standard requests (CMS Interoperability and Prior Authorization Final Rule). If you need a new PA, ask for an expedited review.

Often the cleanest path is asking your insurance plan directly for a "mail-order override" or "specialty pharmacy transfer" because of supply issues. Many plans will approve this in a single phone call. Our prior authorization guide covers the broader process, and the denial appeal guide covers what to do if your insurer says no to the transfer.

Step 5: Talk to your prescriber about format and dose alternatives

Different formats run through different supply chains. KwikPens, multi-dose pens, and single-dose vials are not interchangeable inventory at the wholesaler level. For Zepbound, single-dose vials sold through LillyDirect bypass retail pharmacy distribution entirely. For Wegovy, the pen format is the standard, but NovoCare Pharmacy's direct-ship channel uses a different fulfillment path than walking into a retail counter.

Dose strength availability also varies. If you're stuck on 15 mg Zepbound, your prescriber may be willing to temporarily prescribe two 7.5 mg vials per dose (when clinically appropriate) until your usual strength returns. This is a conversation, not a workaround you do alone. Some plans require a new prior authorization for a dose change; CMS-0057-F's 72-hour expedited window applies.

The same logic works in reverse if you're trying to titrate up and the next strength is unavailable: your prescriber may extend you at your current dose for an extra month rather than send you back to a lower step.

Step 6: Manufacturer cash-pay channels as a backup

If retail and mail-order both come up empty, the manufacturers operate their own direct-to-patient pharmacies that bypass the retail supply chain entirely. These are not insurance plays — you pay cash — but they are the most reliable way to keep treatment going when local pharmacies are out.

NovoCare Pharmacy (Wegovy). Novo Nordisk's direct channel ships Wegovy at a flat $499 per month across all monthly maintenance doses, per the Wegovy.com cost page. New patients to the NovoCare Pharmacy or Wegovy Savings offer can pay $199 for each of the first two monthly fills of the 0.25 mg or 0.5 mg starter doses, with the offer running through June 30, 2026 (NovoCare Wegovy cost page). NovoCare does not write prescriptions; you need a valid Wegovy script from your provider.

LillyDirect (Zepbound vials). Lilly's direct channel ships single-dose Zepbound vials at $299 per month for 2.5 mg, $399 per month for 5 mg, and $449 per month for 7.5 mg, 10 mg, 12.5 mg, and 15 mg under the Self Pay Journey Program. The $449 rate for higher doses took effect February 23, 2026 (Lilly investor announcement on Zepbound vial pricing). LillyDirect also offers Walmart pharmacy retail pickup at the same vial prices for patients who prefer in-person fulfillment.

Pricing on both channels has changed multiple times in the past 18 months and may change again. Verify before you order. For the full cash-pay landscape including telehealth options, see our GLP-1 without insurance guide.

Step 7: A clear note on compounded products

Compounded semaglutide and tirzepatide were widely available during the federal shortage period because Section 503A and 503B of the Food, Drug, and Cosmetic Act allow compounding pharmacies to make copies of FDA-approved drugs that are in shortage. The shortage is over. The legal basis for compounding "essentially a copy" of brand-name semaglutide and tirzepatide ended along with it.

The FDA set grace periods after each resolution: 503A pharmacies could continue compounding semaglutide injection products until April 22, 2025, and 503B outsourcing facilities until May 22, 2025 (FDA: GLP-1 compounder policies). Comparable tirzepatide deadlines closed earlier in 2025. After those dates, the broad shortage-era access path is closed.

Compounded versions are not FDA-approved as finished products. In 2026, compounding remains possible only under narrow patient-specific medical necessity, such as a documented allergy to an inactive ingredient or a dose strength not commercially available — not as a routine cost or supply workaround. If you see a website still selling "compounded GLP-1" subscriptions in 2026, treat that as a serious due-diligence flag. Our compounded vs. brand-name semaglutide guide explains the regulatory picture in detail and our is compounded semaglutide safe guide covers the clinical considerations.

When to bring in a telehealth provider

If you've worked through Steps 1–6 and you're still stuck, a telehealth provider with active pharmacy operations can often close the gap faster than going it alone. They have direct pharmacy relationships, established prior authorization workflows, and staff whose job is to re-route scripts when distribution moves.

Three providers we've reviewed handle this scenario well:

• Ro. Strong at insurance-side coordination and pharmacy transfers, including helping route to NovoCare or LillyDirect when retail is empty. Best general-purpose pick if you have coverage you're trying to keep.
• PlushCare. Insurance-first model. Their care team will work within your plan's pharmacy network to find inventory and re-run prior authorizations when needed.
• Hims. Novo Nordisk official partner with structured access to Wegovy across all doses. Best fit if Wegovy specifically is what you're trying to maintain.

Closing checklist

If your pharmacy just told you they're out:

1. Call your prescriber before you skip a dose.
2. Check zepbound.lilly.com (Zepbound) and start calling independents and hospital outpatient pharmacies (Wegovy or Zepbound).
3. When you find inventory, request a pharmacy transfer through the receiving pharmacy.
4. Call your insurer for a mail-order or specialty pharmacy override if needed.
5. Ask your prescriber about format or temporary dose alternatives if specific doses are dry.
6. Fall back to NovoCare Pharmacy ($499/mo Wegovy) or LillyDirect ($299–$449/mo Zepbound vials) if retail stays empty.
7. Avoid compounded "alternatives" being sold in 2026 — the regulatory basis for routine compounding is gone.

The supply system is messier than it should be, but a missing dose at the pharmacy counter is not the end of your treatment. It's a routing problem with a known set of moves.